About Prima biomed, ltd.

About company

Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima‘s lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission, and soon starting a pilot trial for resected pancreatic cancer. Prima BioMed is listed on the Australian stock exchange, on the NASDAQ in the US and in Germany on the Deutsche Börse in an entry standard.